The addition of CDK4/CDK6 inhibitors to ET markedly improves progression-free survival (PFS) over ET alone in patients with HR+, HER2− advanced breast cancer (ABC) and has become the new standard of care in this setting [3]. Here, CDK6 is linked to breast carcinoma.